Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
Lisata Therapeutics announced a one-for-fifteen reverse stock split of its common stock, with split-adjusted trading on Nasdaq starting at the November 23, 2026 open under the same LSTA symbol. The company also gave a new CUSIP for the shares.
From the press release
LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company’s common stock following the reverse stock split will be 128058 401.
As published for republication. The full text is at GlobeNewswire.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 9:09 AM ESTRead at GlobeNewswire (opens in a new tab)
- SEC EDGARfirst at Nov 19, 2026, 9:18 AM ESTRead at SEC EDGAR (opens in a new tab)
- Seeking Alphafirst at Nov 19, 2026, 10:27 AM ESTRead at Seeking Alpha (opens in a new tab)
Story so far
Reported by 3 sources
Lisata Therapeutics announced a one-for-fifteen reverse stock split of its common stock, with split-adjusted Nasdaq trading under the LSTA symbol starting at the November 23, 2026 open and a new CUSIP.
- Nov 19, 2026, 9:09 AM EST · GlobeNewswire · this storyConfirmedLisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
- Nov 19, 2026, 9:18 AM EST · SEC EDGARConfirmedLisata Therapeutics, Inc. files an 8-K: Material Modifications to Rights of Security Holders
- Nov 19, 2026, 10:27 AM EST · Seeking AlphaConfirmedLisata Therapeutics announces one-for-fifteen reverse stock split
- Nov 19, 2026, 5:10 PM EST · SEC EDGARConfirmedCo-Diagnostics, Inc. files an 8-K: Material Modifications to Rights of Security Holders
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.